Management Team

Kenneth C. Carter, Ph.D.

Executive Chairman

Dr. Ken Carter has helped found and lead several companies including NexImmune, Inc., an immuno-oncology company which he helped spin out from John Hopkins University and served as CEO from inception in 2011 until June 2017. He also co-founded and is currently Chairman of the Board of Noble Life Sciences, Inc, a pre-clinical contract research organization that enables translational science and product development for biotechnology and pharmaceutical companies. Dr. Carter was also co-founder and CEO of Avalon Pharmaceuticals from inception in 1999 until the Company’s merger with Clinical Data in 2009 and led Avalon’s initial public offering on the NASDAQ stock exchange in 2004. Under Dr. Carter’s leadership, Avalon developed a pipeline of cancer drug candidates based on a novel high-throughput genomic screening technology and successfully secured R&D partnerships with Merck, Novartis, Sanofi-Aventis and MedImmune. Dr. Carter has served on numerous corporate and advisory boards including the National BIO Industry Organization, Antidote Therapeutics, Inc., Iterion Pharmaceuticals and the Maryland BioHealth Initiative (BHI). He is also an adjunct faculty member at John Hopkins University.

David Recker


Dr. David Recker is the founding manager of JJK Consulting, a group that advises on pharmaceutical development, with an emphasis on global implementation of small molecule clinical trial design as well as a therapeutic focus on cell therapy. Dr. Recker serves as the Chief Medical Officer of Vericel Corporation, where he has been responsible for clinical development, regulatory affairs, medical and scientific affairs, pharmacovigilance, statistics and data management. Previously, Dr. Recker was Senior Vice President, Clinical Sciences with Takeda's Global Research and Development division, where he implemented global clinical development strategies for several pharmacologic agents in multiple therapeutic areas. Dr. Recker completed his M.D. with distinction at the University of Michigan Medical School.

Thomas Hazel, Ph.D.

Senior Vice President, Research

  • Neuralstem’s Stem Cell Discovery Program Director and Senior Scientist since 1998; Staff Scientist at the NIH Laboratory of Molecular Biology of the National Institute of Neurological Disorders and Stroke in Bethesda; and was a NIH IRTA fellow from 1993-1996.
  • Education: Ph.D., Genetics, University of Illinois College of Medicine; B.A., Biology, Kalamazoo College